R. Amado, M. Wolf, M. Peeters, E. Van-cutsem, S. Siena et al., Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.10, pp.1626-1634, 1623.
DOI : 10.1200/JCO.2007.14.7116

, https://www.cancer.org

C. Arteaga and J. Engelman, ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics, Cancer Cell, vol.25, issue.3, pp.282-303, 2014.
DOI : 10.1016/j.ccr.2014.02.025
URL : https://doi.org/10.1016/j.ccr.2014.02.025

P. Bajpe, A. Prahallad, H. Horlings, I. Nagtegaal, R. Beijersbergen et al., A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity, Oncogene, vol.15, issue.4, p.588, 2014.
DOI : 10.1016/j.ccr.2009.02.023

J. Baker, D. Dutta, D. Watson, T. Maddala, B. Munneke et al., Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer, British Journal of Cancer, vol.9, issue.3, pp.488-495, 2011.
DOI : 10.1126/science.1073096
URL : http://www.nature.com/bjc/journal/v104/n3/pdf/6606054a.pdf

A. Bardelli and S. Siena, Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer, Journal of Clinical Oncology, vol.28, issue.7, pp.1254-1261, 1225.
DOI : 10.1200/JCO.2009.24.6116

A. Bertotti, G. Migliardi, F. Galimi, F. Sassi, D. Torti et al., A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer, Cancer Discovery, vol.1, issue.6, pp.508-523, 2011.
DOI : 10.1158/2159-8290.CD-11-0109

A. Bertotti, E. Papp, S. Jones, V. Adleff, V. Anagnostou et al., The genomic landscape of response to EGFR blockade in colorectal cancer, Nature, vol.486, issue.7572, pp.263-267, 2015.
DOI : 10.1038/nature09208

C. Bokemeyer, I. Bondarenko, A. Makhson, J. Hartmann, J. Aparicio et al., Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.5, pp.663-671, 1229.
DOI : 10.1200/JCO.2008.20.8397

W. De-roock, B. Claes, D. Bernasconi, D. Schutter, J. Biesmans et al., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, The Lancet Oncology, vol.11, issue.8, pp.753-762, 2010.
DOI : 10.1016/S1470-2045(10)70130-3

J. Douillard, A. Rong, and R. Sidhu, RAS mutations in colorectal cancer, N Engl J Med, vol.369, issue.22, pp.2159-2160, 2013.

A. Harle, J. Salleron, G. Perkins, C. Pilati, H. Blons et al., Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers, British Journal of Cancer, vol.61, issue.4, pp.680-685, 2015.
DOI : 10.1093/annonc/mds620
URL : https://hal.archives-ouvertes.fr/hal-01241758

V. Heinemann, F. Rivera, O. Neil, B. Stintzing, S. Koukakis et al., A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer, European Journal of Cancer, vol.67, pp.11-20, 2016.
DOI : 10.1016/j.ejca.2016.07.019

J. Holch, R. I. Stintzing, S. Modest, D. Heinemann, and V. , The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials, European Journal of Cancer, vol.70, pp.87-98, 1029.
DOI : 10.1016/j.ejca.2016.10.007

D. Jonker, C. Karapetis, C. Harbison, O. Callaghan, C. Tu et al., , 2014.

, Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer, Br J Cancer, vol.110, issue.3, pp.648-655

N. Jura, Y. Shan, X. Cao, D. Shaw, and J. Kuriyan, Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3, Proceedings of the National Academy of Sciences, vol.60, issue.Pt 12 Pt 1, pp.21608-21613, 2009.
DOI : 10.1107/S0907444904019158

D. Juric, R. Dienstmann, A. Cervantes, M. Hidalgo, W. Messersmith et al., Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors, Clinical Cancer Research, vol.21, issue.11, pp.2462-2470, 2015.
DOI : 10.1158/1078-0432.CCR-14-2412

C. Karapetis, S. Khambata-ford, D. Jonker, O. Callaghan, C. Tu et al., Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer, New England Journal of Medicine, vol.359, issue.17, pp.1757-1765, 2008.
DOI : 10.1056/NEJMoa0804385

S. Khambata-ford, C. Garrett, N. Meropol, M. Basik, C. Harbison et al., Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab, Journal of Clinical Oncology, vol.25, issue.22, pp.3230-3237, 2007.
DOI : 10.1200/JCO.2006.10.5437

S. Kim, H. Paik, H. Yoon, J. Lee, N. Kim et al., Sex- and gender-specific disparities in colorectal cancer risk, World Journal of Gastroenterology, vol.21, issue.17, pp.5167-5175, 2015.
DOI : 10.1093/jnci/djj159

P. Luraghi, G. Reato, E. Cipriano, F. Sassi, F. Orzan et al., MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR Inhibitors, Cancer Research, vol.74, issue.6, pp.1857-18690008, 1821.
DOI : 10.1158/0008-5472.CAN-13-2340-T

R. Moretto, C. Cremolini, D. Rossini, F. Pietrantonio, F. Battaglin et al., Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer, The Oncologist, vol.21, issue.8, pp.988-994, 2016.
DOI : 10.1634/theoncologist.2016-0084

F. Pietrantonio, F. Petrelli, A. Coinu, D. Bartolomeo, M. Borgonovo et al., Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis, European Journal of Cancer, vol.51, issue.5, pp.587-594, 2015.
DOI : 10.1016/j.ejca.2015.01.054

T. Price, T. Kim, J. Li, S. Cascinu, P. Ruff et al., , 2016.

, Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer, Eur J Cancer, vol.68, pp.51-59

R. Team, A language and environment for statistical computing., R Foundation for Statistical Computing, 2015.

A. Rankin, S. Klempner, R. Erlich, J. Sun, A. Grothey et al., Broad Detection of Alterations, 2016.

A. Rowland, M. Dias, M. Wiese, G. Kichenadasse, and R. Mckinnon, Karapetis CS and Sorich MJ, 2015.

, Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer, Br J Cancer, vol.112, issue.12, pp.1888-1894

A. Sartore-bianchi, M. Martini, F. Molinari, S. Veronese, M. Nichelatti et al., PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies, Cancer Research, vol.69, issue.5, pp.1851-1857, 2009.
DOI : 10.1158/0008-5472.CAN-08-2466
URL : http://cancerres.aacrjournals.org/content/69/5/1851.full.pdf

J. Seligmann, F. Elliott, S. Richman, B. Jacobs, G. Hemmings et al., Wild-Type Advanced Colorectal Cancer, JAMA Oncology, vol.2, issue.5, 2016.
DOI : 10.1001/jamaoncol.2015.6065

N. Song, S. Liu, J. Zhang, J. Liu, L. Xu et al., Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells, International Journal of Molecular Sciences, vol.19, issue.4, pp.5838-5851, 2014.
DOI : 10.1158/1078-0432.CCR-13-0423

S. Tejpar, S. Stintzing, F. Ciardiello, J. Tabernero, E. Van-cutsem et al., Wild-Type Metastatic Colorectal Cancer, JAMA Oncology, vol.3, issue.2, 2016.
DOI : 10.1001/jamaoncol.2016.3797

S. Temraz, D. Mukherji, and A. Shamseddine, Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance, Critical Reviews in Oncology/Hematology, vol.101, pp.151-158, 2016.
DOI : 10.1016/j.critrevonc.2016.03.009

P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan et al., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, JNCI: Journal of the National Cancer Institute, vol.92, issue.3, pp.205-216, 2000.
DOI : 10.1093/jnci/91.6.523

T. Troiani, E. Martinelli, S. Napolitano, D. Vitagliano, L. Ciuffreda et al., Increased TGF-?? as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells, Clinical Cancer Research, vol.19, issue.24, pp.6751-6765, 2013.
DOI : 10.1158/1078-0432.CCR-13-0423

S. Troncale, A. Barbet, L. Coulibaly, E. Henry, B. He et al., , 2012.

, NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data, PLoS One, vol.7, issue.6, pp.38686-32012

E. Van-cutsem, C. Kohne, E. Hitre, J. Zaluski, C. Chien et al., Nippgen J and Rougier P, 2009.

, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, vol.360, issue.14, pp.1408-1417

B. Van-emburgh, A. Sartore-bianchi, D. Nicolantonio, F. Siena, S. Bardelli et al., Acquired resistance to EGFR-targeted therapies in??colorectal cancer, Molecular Oncology, vol.3, issue.6, pp.96-00099, 2014.
DOI : 10.1126/scitranslmed.3002442

S. Van-schaeybroeck, A. Karaiskou-mccaul, D. Kelly, D. Longley, L. Galligan et al., Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy, Clinical Cancer Research, vol.11, issue.20, pp.7480-7489, 2005.
DOI : 10.1158/1078-0432.CCR-05-0328

K. Yonesaka, K. Zejnullahu, I. Okamoto, T. Satoh, F. Cappuzzo et al.,